Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Intellicrown Biotechnology Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner. The data shows that 1 distinct art unit is involved in the review of this pending matter. This single action constitutes the full extent of the company's current pending office action data, concentrated under one examiner and one art unit.
DICKENS, AMELIA NICOLE is the busiest examiner for the portfolio, with 1 busiest examiner pending action. Because there is only 1 pending office action total, this examiner is responsible for the entirety of the company's current pending workload. The use of 1 distinct art unit and 1 distinct examiner indicates a very narrow and focused prosecution path for the company's current filings.
This concentration allows the company to tailor its approach specifically to the requirements of the single examiner and art unit involved. Practitioners can leverage this focus by deeply analyzing the specific examination history of DICKENS, AMELIA NICOLE within the assigned art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKENS, AMELIA NICOLE | 1 | 47.2% | +21.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18807167 | NOVEL MUTANT OF RECOMBINANT GANODERMA LUCIDUM IMMUNOMODULATORY PROTEIN AND USE THEREOF | DICKENS, AMELIA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18807167 | NOVEL MUTANT OF RECOMBINANT GANODERMA LUCIDUM IMMUNOMODULATORY PROTEIN AND USE THEREOF | DICKENS, AMELIA NICOLE | 1645 | §103§112DP | Non-Final OA | — | Pending | Aug 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Intellicrown Biotechnology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amelia Nicole Dickens has the most, with 1 of Shanghai Intellicrown Biotechnology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
